Page 239 - Programme book for The International Liver Congress 2015, EASL ILC 2015
P. 239
P0688 PRECLINICAL CHARACTERISATION OF MIV-802, A ePOSTERS
NOVEL URIDINE NUCLEOTIDE HCV NS5B POLYMERASE
YI P0689 INHIBITOR, FOR TREATMENT OF HEPATITIS C VIRUS
YI P0690 INFECTION
YI P0691 Annelie Lindqvist, Helen Kylefjord, Horst Wähling, Sanja Juric,
YI P0692 Staffan Torssell, Genadiy Kalayanov, Lotta Vrang, Emily Hoberg,
Claes Gustafsson, Anders Eneroth, Erik Lindström, Kristina Wikström,
Paul Targett-Adams, Pedro Pinho, Richard Bethell, Åsa Rosenquist*,
Sweden
THE HEPATITIS C VIRUS CONTRIBUTES TO THE
AGGRAVATION OF THE IMMUNOSUPPRESSIVE
ENVIRONMENT BY INCREASING THE SUPPRESSIVE
ACTIVITY OF NATURAL REGULATORY T CELLS
Laurissa Ouaguia*, Olivier Morales, Czeslaw Wychowski,
Arnaud Carpentier, Lynda Aoudjehane, Jean Dubuisson,Yvon Calmus,
Yvan deLaunoit, Filomena Conti, Nadira Delhem, France
IFN-FREE THERAPY FOR CHRONIC HCV:
TRANSCRIPTOMICS AND NK CELL ANALYSES
Michelle Spaan, Gertine van Oord, Kim Kreefft, Jun Hou,
Bettina Hansen, Harry Janssen, Robert de Knegt, Andre Boonstra*,
The Netherlands
KNOCKDOWN OF LYSOPHOSPHATIDYLCHOLINE
ACYLTRANSFERASE 1 (LPCAT1) INCREASES BOTH THE
SECRETION OF VERY-LOW-DENSITY LIPOPROTEINS
(VLDL) AND THE INFECTIVITY OF HEPATITIS C VIRUS
(HCV)
Matthieu Lemasson*, Frauke Beilstein, Véronique Pène,
Arielle R. Rosenberg, Sylvie Demignot, France
PKC/AP-1 SIGNALING DRIVES TRANSCRIPTION OF
INTERFERON-STIMULATED GENES AND EXERTS POTENT
ANTIVIRAL ACTIVITY AGAINST HEPATITIS C AND E
VIRUSES
Wenshi Wang*,Yijin Wang, Xinying Zhou,Yuebang Yin, Lei Xu,
Dave Sprengers, Herold J. Metselaar,Yannick Debing, Johan Neyts,
Maikel P. Peppelenbosch, Qiuwei Pan, The Netherlands
Vienna, Austria • April 22–26, 2015 239
NOVEL URIDINE NUCLEOTIDE HCV NS5B POLYMERASE
YI P0689 INHIBITOR, FOR TREATMENT OF HEPATITIS C VIRUS
YI P0690 INFECTION
YI P0691 Annelie Lindqvist, Helen Kylefjord, Horst Wähling, Sanja Juric,
YI P0692 Staffan Torssell, Genadiy Kalayanov, Lotta Vrang, Emily Hoberg,
Claes Gustafsson, Anders Eneroth, Erik Lindström, Kristina Wikström,
Paul Targett-Adams, Pedro Pinho, Richard Bethell, Åsa Rosenquist*,
Sweden
THE HEPATITIS C VIRUS CONTRIBUTES TO THE
AGGRAVATION OF THE IMMUNOSUPPRESSIVE
ENVIRONMENT BY INCREASING THE SUPPRESSIVE
ACTIVITY OF NATURAL REGULATORY T CELLS
Laurissa Ouaguia*, Olivier Morales, Czeslaw Wychowski,
Arnaud Carpentier, Lynda Aoudjehane, Jean Dubuisson,Yvon Calmus,
Yvan deLaunoit, Filomena Conti, Nadira Delhem, France
IFN-FREE THERAPY FOR CHRONIC HCV:
TRANSCRIPTOMICS AND NK CELL ANALYSES
Michelle Spaan, Gertine van Oord, Kim Kreefft, Jun Hou,
Bettina Hansen, Harry Janssen, Robert de Knegt, Andre Boonstra*,
The Netherlands
KNOCKDOWN OF LYSOPHOSPHATIDYLCHOLINE
ACYLTRANSFERASE 1 (LPCAT1) INCREASES BOTH THE
SECRETION OF VERY-LOW-DENSITY LIPOPROTEINS
(VLDL) AND THE INFECTIVITY OF HEPATITIS C VIRUS
(HCV)
Matthieu Lemasson*, Frauke Beilstein, Véronique Pène,
Arielle R. Rosenberg, Sylvie Demignot, France
PKC/AP-1 SIGNALING DRIVES TRANSCRIPTION OF
INTERFERON-STIMULATED GENES AND EXERTS POTENT
ANTIVIRAL ACTIVITY AGAINST HEPATITIS C AND E
VIRUSES
Wenshi Wang*,Yijin Wang, Xinying Zhou,Yuebang Yin, Lei Xu,
Dave Sprengers, Herold J. Metselaar,Yannick Debing, Johan Neyts,
Maikel P. Peppelenbosch, Qiuwei Pan, The Netherlands
Vienna, Austria • April 22–26, 2015 239
